Newest research
New Data Forecast More Oral PDE4 Inhibitors for Psoriasis Medscape 3/24/2023 Orismilast is a new Phosphodiesterase-4 inhibitor, in phase two trials showing promise, is said to be 2 – 5 times more effective than those on the market. The chief competitor will be Daliresp (roflumilast), now generic, that is available for $35/month from Walmart. Another […]